SPRYCEL\u00ae is a prescription medicine used to treat adults who have: \u2022 newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. \u2022 Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including Gleevec\u00ae (imatinib mesylate). \u2022 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment. It is not known if SPRYCEL is safe and effective in children younger than 18 years old.<\/p>\n
Active ingredient: dasatinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium dioxide, and polyethylene glycol.<\/p>\n
If Dasatinib Tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
SPRYCEL is a kinase inhibitor indicated for the treatment of \u2022 newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.<\/p>\n
Approval Date: 2006 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cDasatinib Tablets\u201d based on the information you provide.<\/p>\n
\nProprietary Name: On Request
\nActive Ingredient(s): Dasatinib Tablets
\nDosage Forms And Strengths: Tablets: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.
\nCompany: Bristol-Myers Squibb
\nCurrent indications: chronic Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
\nMedicine Approved By: \u2013<\/strong>\u00a0European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n